AIMS: In patients with renal disease the cardiovascular risk is greatly increased, and
endothelial dysfunction is assumed to play a pivotal role in this process. Therefore we …

We tested the activity of nebivolol, a β 1-selective blocker with respect to nitric oxide (NO)
and peroxynitrite (ONOO−) generation in the endothelium of normotensive Wistar Kyoto …

Background. Altered renal vasodilatation and oxidative stress are important mechanisms of
contrast-induced nephropathy (CIN). The aim of the present study was to assess the effect of …

We aim to determine whether nebivolol has a better effect on endothelial dysfunction
compared with other β-blockers or other classes of antihypertensive drugs. Searches of the …

Background: Nebivolol is a selective β1-adrenergic receptor antagonist that causes a direct
vasodilator effect attributed to the action on vascular nitric oxide (NO). This study aimed to …

This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

BACKGROUND: Many diabetics develop hypertension, and it is a major risk factor for
cardiovascular and microvascular complications. OBJECTIVE: To review a case study of a …

Nebivolol is a lipophilic β 1-blocker. It is devoid of intrinsic sympathomimetic or membrane
stabilising activity but appears to have nitric oxide-mediated vasodilatory effects. Nebivolol is …

Although β-blockers have been endorsed by guidelines committees for the treatment of
patients with hypertension, particularly those with significant CVD and high CVD risk, there …

Background. Nebivolol is a highly selective β1-adrenoreceptor antagonist with vasodilating
properties. This study investigated its effect on quality of life (QoL) and blood pressure (BP) …